Trial Profile

A two-part, open-label, comparative, single-dose, randomized, five-treatment, three-way crossover sequential study to assess the relative bioavailability of entrectinib capsule compared to nasogastric and oral administration of suspension in healthy subjects

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 19 Oct 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Entrectinib (Primary) ; Entrectinib; Entrectinib
Indications Acute myeloid leukaemia; Brain metastases; Malignant melanoma; Non-small cell lung cancer; Solid tumours; Uveal melanoma
Focus Pharmacokinetics
Sponsors Roche

19 Oct 2022 Status changed from recruiting to completed.
10 Aug 2022 New trial record
08 Aug 2022 The recruitment start date has been changed from 03 Aug 2022 to 10 Aug 2022. Full patient recruitment expected to be completed by 3 Oct 2022.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com